Advertise
Resources
Member, Beacon International Group, Ltd.
The prices of weight loss drugs are under scrutiny as the number of Americans eligible for these treatments rises, Axios reports. The cost of these drugs, even after rebates and discounts, would need to drop by 90% to avoid increasing the national deficit, according to the Congressional Budget Office. The CBO also said it expects semaglutide, the active ingredient in Ozempic and Wegovy, to be selected for Medicare price negotiation within the next few years.